Suscripción a Biblioteca: Guest
Portal Digitalde Biblioteca Digital eLibros Revistas Referencias y Libros de Ponencias Colecciones
Critical Reviews™ in Therapeutic Drug Carrier Systems
Factor de Impacto: 2.9 Factor de Impacto de 5 años: 3.72 SJR: 0.736 SNIP: 0.818 CiteScore™: 4.6

ISSN Imprimir: 0743-4863
ISSN En Línea: 2162-660X

Volumes:
Volumen 37, 2020 Volumen 36, 2019 Volumen 35, 2018 Volumen 34, 2017 Volumen 33, 2016 Volumen 32, 2015 Volumen 31, 2014 Volumen 30, 2013 Volumen 29, 2012 Volumen 28, 2011 Volumen 27, 2010 Volumen 26, 2009 Volumen 25, 2008 Volumen 24, 2007 Volumen 23, 2006 Volumen 22, 2005 Volumen 21, 2004 Volumen 20, 2003 Volumen 19, 2002 Volumen 18, 2001 Volumen 17, 2000 Volumen 16, 1999 Volumen 15, 1998 Volumen 14, 1997 Volumen 13, 1996 Volumen 12, 1995

Critical Reviews™ in Therapeutic Drug Carrier Systems

DOI: 10.1615/CritRevTherDrugCarrierSyst.v18.i6.40
16 pages

In Vivo Applications of PEG Liposomes: Unexpected Observations

Peter Laverman
Department of Nuclear Medicine, University Medical Center Nijmegen, Nijmegen, The Netherlands
Otto C. Boerman
Department of Nuclear Medicine, University Medical Center Nijmegen, Nijmegen, The Netherlands
Wim J. G. Oyen
Department of Nuclear Medicine, University Medical Center Nijmegen, Nijmegen, The Netherlands
Frans H. M. Corstens
Department of Nuclear Medicine, University Medical Center Nijmegen, Nijmegen, The Netherlands
Gert Storm
Utrecht Institute for Pharmaceutical Science, Utrecht University, Utrecht, The Netherlands

SINOPSIS

Recent studies with PEG liposomes in patients have consistently shown that liposomes can induce side effects (flushing, tightness of the chest). Furthermore, the blood clearance of PEG liposomes was shown to be dose-dependent: at lipid doses lower than 1 mmol/kg, PEG liposomes do not show the long-circulation property but instead are cleared relatively rapidly from the bloodstream. Another remarkable observation was that repeated injections of PEG liposomes led to significant pharmacokinetic changes: the circulatory half-life of a second dose of radiolabeled PEG liposomes dramatically decreased when given from 5 days to up to 4 weeks after a first injection. In these three unexpected phenomena, proteins of the complement system seem to play a key role.Therefore, one has to consider that PEG liposomes are not inert drug-carrying vehicles in vivo. Pharmacological effects can occur, induced solely by using liposomal particles irrespective of the drug content.


Articles with similar content:

Microparticles and Nanoparticles as Delivery Systems for DNA Vaccines
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.20, 2003, issue 2&3
Zhengrong Cui, Russell J. Mumper
The Effect of Recombinant Human Tumor Necrosis Factor-a on Ehrlich Ascites Tumor Growth
Journal of Environmental Pathology, Toxicology and Oncology, Vol.21, 2002, issue 1
Henryk F. Nowak, Mariola Sulkowska, Slawomir Terlikowski
The Quartz Hazard: Effects of Surface and Matrix on Inflammogenic Activity
Journal of Environmental Pathology, Toxicology and Oncology, Vol.20, 2001, issue Suppl.1
Paul Borm, Ken Donaldson, Rodger Duffin, Anna Clouter, Vicki Stone, Roel Schins
Delivery of Biotherapeutics by Inhalation Aerosol
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.12, 1995, issue 2-3
Ralph W. Niven
Differential Effects of Psychoactive Drugs in Adolescents and Adults
Critical Reviews™ in Neurobiology, Vol.17, 2005, issue 2
Sari Izenwasser